Literature DB >> 20018627

Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation.

Tina Dietrich1, Felix Bock, Don Yuen, Deniz Hos, Björn O Bachmann, Grit Zahn, Stanley Wiegand, Lu Chen, Claus Cursiefen.   

Abstract

The purpose of this study was to determine the relative importance of blood vessels (hemangiogenesis) versus lymphatic vessels (lymphangiogenesis) in mediating immunological responses after transplantation. Using the murine model of corneal transplantation, graft survival was compared in differentially prevascularized and avascular recipient beds. Donor corneas (C57BL/6) were transplanted into uninflamed or inflamed avascular, prehemvascularized only or prehemvascularized and prelymphvascularized recipient murine eyes (BALB/C). Selective inhibition of lymphangiogenesis was achieved using antivascular endothelial growth factor receptor 3 Abs and anti-integrin alpha5 small molecules. Grafts placed into only prehemvascularized recipient beds had a similarly good graft survival compared with grafts placed into completely avascular, normal recipients, whereas the pre-existence of lymphatic vessels significantly deteriorated corneal graft survival (p < 0.05). Lymphatic vessels seem to contribute significantly to graft rejection after (corneal) transplantation. That may allow for selective, temporary, perioperative antilymphangiogenic treatment to promote graft survival without affecting blood vessels, even after solid organ transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018627      PMCID: PMC4725297          DOI: 10.4049/jimmunol.0903180

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  First year changes of myocardial lymphatic endothelial markers in heart transplant recipients.

Authors:  Hans J Geissler; Alexey Dashkevich; Uwe M Fischer; Jochen W U Fries; Ferdinand Kuhn-Régnier; Klaus Addicks; Uwe Mehlhorn; Wilhelm Bloch
Journal:  Eur J Cardiothorac Surg       Date:  2006-01-24       Impact factor: 4.191

2.  Design and synthesis of a new class of selective integrin alpha5beta1 antagonists.

Authors:  Roland Stragies; Frank Osterkamp; Gunther Zischinsky; Doerte Vossmeyer; Holger Kalkhof; Ulf Reimer; Grit Zahn
Journal:  J Med Chem       Date:  2007-07-06       Impact factor: 7.446

3.  Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells.

Authors:  H J Kaplan; J W Streilein; T R Stevens
Journal:  J Immunol       Date:  1975-09       Impact factor: 5.422

4.  Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation.

Authors:  Satoru Yamagami; M Reza Dana; Tadahiko Tsuru
Journal:  Cornea       Date:  2002-05       Impact factor: 2.651

5.  alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation.

Authors:  Tatsuma Okazaki; Amy Ni; Oluwasheyi A Ayeni; Peter Baluk; Li-Chin Yao; Doerte Vossmeyer; Gunther Zischinsky; Grit Zahn; Jochen Knolle; Claudia Christner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

6.  Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group.

Authors:  M G Maguire; W J Stark; J D Gottsch; R D Stulting; A Sugar; N E Fink; A Schwartz
Journal:  Ophthalmology       Date:  1994-09       Impact factor: 12.079

7.  Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study.

Authors:  Michael Küchle; Claus Cursiefen; Nhung X Nguyen; Achim Langenbucher; Berthold Seitz; Hartmut Wenkel; Peter Martus; Gottfried O H Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-06-21       Impact factor: 3.117

8.  Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade.

Authors:  Tina Dietrich; Jasmine Onderka; Felix Bock; Friedrich E Kruse; Dörte Vossmeyer; Roland Stragies; Grit Zahn; Claus Cursiefen
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

9.  Effect of local macrophage depletion on cellular immunity and tolerance evoked by corneal allografts.

Authors:  Tanja P A M Slegers; Ruth van der Gaag; Nico van Rooijen; Gabriel van Rij; J Wayne Streilein
Journal:  Curr Eye Res       Date:  2003-02       Impact factor: 2.424

10.  Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation.

Authors:  Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Bronislaw Pytowski; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-10-02       Impact factor: 3.117

View more
  119 in total

Review 1.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Relations between lymphangiogenesis and the size of pterygium.

Authors:  Lin Liu; Shi-Qi Ling; Qiao-Li Li; Tao Wang; Hui Ye; Jie-Zhen Yang; Xiu-Hua Jia
Journal:  Int J Ophthalmol       Date:  2012-06-18       Impact factor: 1.779

3.  HA-ving lymphatics improves lung transplantation.

Authors:  Jonathan S Maltzman; Hasina Outtz Reed; Mark L Kahn
Journal:  J Clin Invest       Date:  2015-10-20       Impact factor: 14.808

4.  [Prevention and management of complications in Descemet membrane endothelial keratoplasty (DMEK) and Descemet stripping automated endothelial keratoplasty (DSAEK)].

Authors:  C Cursiefen; P Steven; S Roters; L M Heindl
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

Review 5.  Lymphatic function and immune regulation in health and disease.

Authors:  Shan Liao; Timothy P Padera
Journal:  Lymphat Res Biol       Date:  2013-09-11       Impact factor: 2.589

6.  Vascular endothelial growth factor-C ameliorates renal interstitial fibrosis through lymphangiogenesis in mouse unilateral ureteral obstruction.

Authors:  Shoko Hasegawa; Toshiaki Nakano; Kumiko Torisu; Akihiro Tsuchimoto; Masahiro Eriguchi; Naoki Haruyama; Kosuke Masutani; Kazuhiko Tsuruya; Takanari Kitazono
Journal:  Lab Invest       Date:  2017-10-30       Impact factor: 5.662

7.  Combined blockade of VEGFR-2 and VEGFR-3 inhibits inflammatory lymphangiogenesis in early and middle stages.

Authors:  Don Yuen; Bronek Pytowski; Lu Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-20       Impact factor: 4.799

Review 8.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

9.  Impaired humoral immunity and tolerance in K14-VEGFR-3-Ig mice that lack dermal lymphatic drainage.

Authors:  Susan N Thomas; Joseph M Rutkowski; Miriella Pasquier; Emma L Kuan; Kari Alitalo; Gwendalyn J Randolph; Melody A Swartz
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

10.  Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.

Authors:  Parisa Emami-Naeini; Thomas H Dohlman; Masahiro Omoto; Takaaki Hattori; Yihe Chen; Hyun Soo Lee; Sunil K Chauhan; Reza Dana
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-05       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.